About CVS Health (NYSE:CVS)
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc. (Omnicare) and Omnicare's long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. It operates through three segments: Pharmacy Services, Retail/LTC and Corporate. The Pharmacy Services Segment provides a range of pharmacy benefit management (PBM) solutions to its clients. As of December 31, 2016, the Retail/LTC Segment included 9,709 retail locations (of which 7,980 were its stores that operated a pharmacy and 1,674 were its pharmacies located within Target Corporation (Target) stores), its online retail pharmacy Websites, CVS.com, Navarro.com and Onofre.com.br, 38 onsite pharmacy stores, its long-term care pharmacy operations and its retail healthcare clinics.
Industry, Sector and Symbol
Industry Drug Retailers
SectorDrug Retailers - NEC
Trailing P/E Ratio16.5
Forward P/E Ratio13.56
Sales & Book Value
Annual Sales$177.53 billion
Price / Sales0.46
Cash Flow$8.22 per share
Price / Cash9.71
Book Value$34.54 per share
Price / Book2.31
Net Income$5.32 billion
Return on Equity16.96%
Return on Assets6.36%
CVS Health (NYSE:CVS) Frequently Asked Questions
What is CVS Health's stock symbol?
CVS Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVS."
How often does CVS Health pay dividends? What is the dividend yield for CVS Health?
CVS Health declared a quarterly dividend on Friday, December 29th. Shareholders of record on Wednesday, January 24th will be given a dividend of $0.50 per share on Friday, February 2nd. This represents a $2.00 annualized dividend and a yield of 2.50%. The ex-dividend date of this dividend is Tuesday, January 23rd. View CVS Health's Dividend History.
How were CVS Health's earnings last quarter?
CVS Health Corp (NYSE:CVS) announced its earnings results on Monday, November, 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.49 by $0.01. The pharmacy operator had revenue of $46.18 billion for the quarter, compared to the consensus estimate of $46.17 billion. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm's quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.64 earnings per share. View CVS Health's Earnings History.
When will CVS Health make its next earnings announcement?
What guidance has CVS Health issued on next quarter's earnings?
CVS Health issued an update on its fourth quarter earnings guidance on Monday, November, 6th. The company provided EPS guidance of $1.88-1.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.91.
Where is CVS Health's stock going? Where will CVS Health's stock price be in 2018?
20 analysts have issued 12-month target prices for CVS Health's shares. Their predictions range from $73.00 to $106.67. On average, they expect CVS Health's share price to reach $87.77 in the next year. View Analyst Ratings for CVS Health.
What are Wall Street analysts saying about CVS Health stock?
Here are some recent quotes from research analysts about CVS Health stock:
- 1. Guggenheim analysts commented, " Our recent meetings with CEO Larry Merlo, CFO Dave Denton, and VP-IR Nancy Christal further reinforced our confidence in 10% secular growth, which we believe the market is currently undervaluing, at a 13x P/E on somewhat depressed 2017E EPS. Bottom line, even in the face of secular gross margin erosion, in both segments, we believe the company should be able to grow EBIT by 5% on the back of a) natural growth in specialty Rx, b) increasingly rapid product innovation, c) a broadening set of productive relationships, and d) both COGS and SG&A reductions. In our view, this growth merits a valuation closer to a market multiple'we reiterate our Buy rating and $90 PT, implying 15% upside from current levels." (3/28/2017)
- 2. Evercore ISI analysts commented, "While the quarter proved generally uneventful and guidance was reiterated on the surface (albeit some moving parts below ' dollar profit targets were unchanged in our view ' much of the delta related to where 4Q came out vs mid-point and lower inflation outlook), investors have reacted negatively to the lack of clarity on several key issues with respect to business model risk that in our minds is unlikely to dissipate until later in the year. We think management did an admirable job on the DIR fee issue and a reasonable job on gross to net / rebates, but the reality is that policy noise is unlikely to dissipate and the outlook for 2018 won't start to gain clarity until the summer. We think once we get initial color on the PBM selling season, a better understanding of underlying pharmacy share shifts and profit headwinds and ultimately gain a better picture of 2018 the multiple may start to see some relief. Until then CVS shares remain inexpensive and highly leveraged to tax reform and it appears as if many years of execution are being overshadowed by a tough 18 month stretch. Given how far shares have fallen and in our view strong FCF yield support we retain our Buy rating but acknowledge the path to returns from here is likely most appropriate for those with a multi-year time horizon and a 'deep value' focus." (2/9/2017)
Are investors shorting CVS Health?
CVS Health saw a increase in short interest in December. As of December 29th, there was short interest totalling 32,959,903 shares, an increase of 5.5% from the December 15th total of 31,227,273 shares. Based on an average daily volume of 7,767,991 shares, the short-interest ratio is presently 4.2 days. Approximately 3.3% of the shares of the stock are short sold.
Who are some of CVS Health's key competitors?
Some companies that are related to CVS Health include International Business Machines (IBM), British American Tobacco (BTI), 3M (MMM), Total (TOT), McDonald's (MCD), General Electric (GE), BP (BP), SAP (SAP), PetroChina (PTR), Altria Group (MO), BHP Billiton (BHP), BHP Billiton (BBL), Royal Bank of Canada (RY), Honeywell International (HON), Medtronic (MDT), Banco Santander (SAN), United Parcel Service (UPS) and Novo Nordisk A/S (NVO).
Who are CVS Health's key executives?
CVS Health's management team includes the folowing people:
- David Wyatt Dorman, Independent Chairman of the Board (Age 63)
- Larry J. Merlo, President, Chief Executive Officer, Director (Age 61)
- David M. Denton, Chief Financial Officer, Executive Vice President (Age 52)
- Jonathan C. Roberts, Chief Operating Officer, Executive Vice President (Age 61)
- Lisa G. Bisaccia, Chief Human Resource Officer, Executive Vice President (Age 61)
- Stephen J. Gold, Executive Vice President, Chief Information Officer (Age 57)
- Thomas M. Moriarty, Executive Vice President, General Counsel, Chief Health Strategy Officer (Age 53)
- Troyen A. Brennan M.D., Executive Vice President, Chief Medical Officer (Age 62)
- Helena B. Foulkes, Executive Vice President, President of CVS - Pharmacy (Age 52)
- J. David Joyner, Executive Vice President (Age 52)
Who owns CVS Health stock?
CVS Health's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.57%), Schwab Charles Investment Management Inc. (0.43%), Hexavest Inc. (0.13%), Factory Mutual Insurance Co. (0.13%), DnB Asset Management AS (0.12%) and CGOV Asset Management (0.11%). Company insiders that own CVS Health stock include Andrew Sussman, David M Denton, Eva C Boratto, Helena Foulkes, Jonathan C Roberts, Larry J Merlo, Lisa Bisaccia, Richard J Swift, Stephen J Gold, Thomas M Moriarty and Troyen A Brennan. View Institutional Ownership Trends for CVS Health.
Who sold CVS Health stock? Who is selling CVS Health stock?
CVS Health's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, LVM Capital Management Ltd. MI, Factory Mutual Insurance Co., Clark Estates Inc. NY, Edge Wealth Management LLC, Pennsylvania Trust Co, Trust Department MB Financial Bank N A and First Citizens Bank & Trust Co.. Company insiders that have sold CVS Health company stock in the last year include Andrew Sussman, David M Denton, Eva C Boratto, Helena Foulkes, Jonathan C Roberts, Larry J Merlo, Lisa Bisaccia, Richard J Swift, Thomas M Moriarty and Troyen A Brennan. View Insider Buying and Selling for CVS Health.
Who bought CVS Health stock? Who is buying CVS Health stock?
CVS Health's stock was acquired by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Hexavest Inc., USS Investment Management Ltd, Alta Capital Management LLC, Franklin Street Advisors Inc. NC, Schwab Charles Investment Management Inc., CGOV Asset Management and Wasatch Advisors Inc.. View Insider Buying and Selling for CVS Health.
How do I buy CVS Health stock?
Shares of CVS Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CVS Health's stock price today?
One share of CVS Health stock can currently be purchased for approximately $79.86.
How big of a company is CVS Health?
CVS Health has a market capitalization of $80.90 billion and generates $177.53 billion in revenue each year. The pharmacy operator earns $5.32 billion in net income (profit) each year or $4.84 on an earnings per share basis. CVS Health employs 250,000 workers across the globe.
How can I contact CVS Health?
CVS Health's mailing address is 1 Cvs Dr, WOONSOCKET, RI 02895-6146, United States. The pharmacy operator can be reached via phone at +1-401-7651500 or via email at [email protected]
MarketBeat Community Rating for CVS Health (CVS)MarketBeat's community ratings are surveys of what our community members think about CVS Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
CVS Health (NYSE:CVS) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.70||2.63||2.67||2.63|
|Ratings Breakdown: ||0 Sell Rating(s)|
7 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
7 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$87.77||$86.10||$88.65||$94.27|
|Price Target Upside: ||10.41% upside||20.10% upside||16.63% upside||20.97% upside|
CVS Health (NYSE:CVS) Consensus Price Target History
CVS Health (NYSE:CVS) Analyst Ratings History
(Data available from 1/22/2016 forward)
CVS Health (NYSE:CVS) Earnings History and Estimates Chart
CVS Health (NYSE CVS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2017||Q3 2017||$1.49||$1.50||$46.17 billion||$46.18 billion||View||N/A|
|8/8/2017||Q2 2017||$1.31||$1.33||$45.36 billion||$45.69 billion||View||Listen|
|5/2/2017||Q1 2017||$1.10||$1.17||$44.20 billion||$44.51 billion||View||Listen|
|2/9/2017||Q416||$1.67||$1.71||$46.56 billion||$46.00 billion||View||Listen|
|11/8/2016||Q316||$1.57||$1.64||$45.29 billion||$44.60 billion||View||Listen|
|8/2/2016||Q216||$1.30||$1.32||$44.28 billion||$43.70 billion||View||N/A|
|5/3/2016||Q116||$1.16||$1.18||$43.01 billion||$43.20 billion||View||N/A|
|2/9/2016||Q415||$1.53||$1.53||$41.12 billion||$41.15 billion||View||N/A|
|10/30/2015||Q315||$1.29||$1.28||$37.81 billion||$38.50 billion||View||Listen|
|8/4/2015||Q215||$1.20||$1.22||$37.18 billion||$37.20 billion||View||N/A|
|5/1/2015||Q115||$1.08||$1.14||$35.93 billion||$36.30 billion||View||N/A|
|2/10/2015||Q414||$1.21||$1.21||$36.06 billion||$37.06 billion||View||N/A|
|11/4/2014||Q314||$1.13||$1.15||$34.74 billion||$35.00 billion||View||N/A|
|8/5/2014||Q214||$1.10||$1.13||$33.47 billion||$34.60 billion||View||N/A|
|5/2/2014||Q114||$1.05||$1.02||$32.31 billion||$32.70 billion||View||N/A|
|2/11/2014||Q413||$1.11||$1.12||$32.67 million||$32.80 million||View||N/A|
|11/5/2013||Q313||$1.02||$1.05||$31.53 billion||$32.00 billion||View||Listen|
|8/6/2013||Q2 2013||$0.96||$0.97||$31.13 billion||$31.25 billion||View||Listen|
|5/1/2013||Q113||$0.79||$0.83||$30.36 billion||$30.76 billion||View||Listen|
|2/6/2013||Q4 2012||$1.10||$1.14||$31.13 billion||$31.40 billion||View||Listen|
|11/6/2012||Q312||$0.84||$0.85||$30.09 billion||$30.23 billion||View||N/A|
CVS Health (NYSE:CVS) Earnings Estimates
2018 EPS Consensus Estimate: $6.57
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
CVS Health (NYSE:CVS) Dividend Information
|Dividend Growth:||22.10% (3 Year Average)|
|Payout Ratio:||41.32% (Trailing 12 Months of Earnings) |
33.96% (Based on This Year's Estimates)
31.06% (Based on Next Year's Estimates)
|Track Record:||10 Years of Consecutive Dividend Growth|
CVS Health (NYSE:CVS) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
CVS Health (NYSE CVS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.61%
Institutional Ownership Percentage: 81.69%
CVS Health (NYSE CVS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/21/2017||Lisa Bisaccia||EVP||Sell||29,445||$75.00||$2,208,375.00||15,556|| |
|10/2/2017||Thomas M Moriarty||EVP||Sell||20,547||$81.17||$1,667,799.99||43,178|| |
|9/18/2017||Jonathan C Roberts||COO||Sell||85,743||$83.14||$7,128,673.02||119,555|| |
|9/15/2017||Helena Foulkes||EVP||Sell||39,340||$81.88||$3,221,159.20||84,337|| |
|9/13/2017||Larry J Merlo||Insider||Sell||241,150||$83.07||$20,032,330.50||299,255|| |
|9/11/2017||David M Denton||CFO||Sell||237,078||$79.65||$18,883,262.70||141,096|| |
|9/11/2017||Thomas M Moriarty||EVP||Sell||90,267||$79.61||$7,186,155.87||70,102|| |
|8/16/2017||Richard J Swift||Director||Sell||2,500||$79.62||$199,050.00||3,258|| |
|6/26/2017||Helena Foulkes||EVP||Sell||20,333||$80.00||$1,626,640.00||59,301|| |
|6/19/2017||Helena Foulkes||EVP||Sell||20,332||$76.98||$1,565,157.36||59,300|| |
|6/12/2017||David M Denton||CFO||Sell||230,510||$80.00||$18,440,800.00||176,983|| |
|3/21/2017||Troyen A Brennan||EVP||Sell||23,849||$78.73||$1,877,631.77||94,309|| |
|3/17/2017||Eva C Boratto||EVP||Sell||6,029||$79.60||$479,908.40||41,614|| |
|3/13/2017||Andrew Sussman||EVP||Sell||14,104||$80.40||$1,133,961.60||22,801|| |
|3/10/2017||David M Denton||CFO||Sell||95,618||$80.68||$7,714,460.24||250,335|| |
|2/16/2017||Jonathan C Roberts||EVP||Sell||61,196||$80.00||$4,895,680.00||89,955|| |
|5/5/2016||Larry J Merlo||CEO||Sell||38,247||$105.00||$4,015,935.00||280,381|| |
|5/5/2016||Troyen A Brennan||EVP||Sell||7,517||$105.00||$789,285.00||69,601|| |
|4/1/2016||Stephen J Gold||EVP||Sell||21,922||$105.00||$2,301,810.00||42,048|| |
|3/9/2016||Larry J Merlo||CEO||Sell||38,247||$100.00||$3,824,700.00||261,287|| |
|2/11/2016||Jonathan C. Roberts||EVP||Sell||23,355||$92.86||$2,168,745.30||75,315|| |
|2/1/2016||Larry J. Merlo||CEO||Sell||46,393||$96.14||$4,460,223.02||561,059|| |
|1/11/2016||Larry J. Merlo||CEO||Sell||46,393||$95.00||$4,407,335.00||161,613|| |
|10/27/2015||Troyen A. Brennan||EVP||Sell||23,603||$105.00||$2,478,315.00||43,858|| |
|7/20/2015||Eva C Boratto||SVP||Sell||22,107||$110.34||$2,439,286.38|| |
|7/15/2015||Lisa Bisaccia||EVP||Sell||49,908||$110.00||$5,489,880.00|| |
|6/1/2015||C David Brown II||Director||Sell||10,000||$102.57||$1,025,700.00|| |
|5/1/2015||C David Brown II||Director||Sell||15,000||$100.27||$1,504,050.00|| |
|4/10/2015||Andrew Sussman||EVP||Sell||17,638||$102.38||$1,805,778.44|| |
|4/2/2015||Troyen A Brennan||EVP||Sell||33,384||$102.48||$3,421,192.32|| |
|3/23/2015||Troyen A Brennan||EVP||Sell||33,274||$104.94||$3,491,773.56|| |
|3/20/2015||C David Brown II||Director||Sell||25,000||$104.30||$2,607,500.00|| |
|1/7/2015||Jonathan C Roberts||EVP||Sell||86,487||$95.31||$8,243,075.97|| |
|1/5/2015||Larry J Merlo||CEO||Sell||144,144||$94.30||$13,592,779.20|| |
|1/2/2015||Andrew Sussman||SVP||Sell||4,220||$95.67||$403,727.40|| |
|1/2/2015||Per Gh Lofberg||EVP||Sell||347,343||$95.28||$33,094,841.04|| |
|11/7/2014||Helena Foulkes||EVP||Sell||46,325||$88.06||$4,079,379.50|| |
|10/27/2014||Lisa Bisaccia||SVP||Sell||33,507||$85.00||$2,848,095.00|| |
|9/2/2014||Andrew Sussman||SVP||Sell||9,020||$79.45||$716,639.00|| |
|8/6/2014||J. David Joyner||EVP||Sell||123,516||$76.10||$9,399,567.60|| |
|7/21/2014||Eva C Boratto||SVP||Sell||22,107||$76.77||$1,697,154.39|| |
|7/1/2014||David M Denton||CFO||Sell||74,989||$75.88||$5,690,165.32|| |
|4/2/2014||Eva Boratto||SVP||Sell||17,108||$74.51||$1,274,717.08||6,998|| |
|3/31/2014||Troyen Brennan||EVP||Sell||18,867||$74.33||$1,402,384.11||56,187|| |
|1/3/2014||David Denton||CFO||Sell||14,113||$70.50||$994,966.50||85,869|| |
|1/3/2014||Per Gh Lofberg||EVP||Sell||790,888||$70.54||$55,789,239.52||219,871|| |
|1/2/2014||Jonathan Roberts||EVP||Sell||162,192||$70.61||$11,452,377.12||40,563|| |
|1/2/2014||Larry Merlo||CEO||Sell||228,875||$70.76||$16,195,195.00||408,649|| |
|12/10/2013||Lisa Bisaccia||SVP||Sell||12,057||$68.00||$819,876.00||27,233|| |
|11/18/2013||Troyen Brennan||EVP||Sell||35,387||$65.61||$2,321,741.07||56,187|| |
|10/18/2013||Eva C Boratto||SVP||Sell||11,053||$60.50||$668,706.50|| |
|10/11/2013||Eva Boratto||SVP||Sell||11,053||$59.50||$657,653.50||19,448|| |
|9/13/2013||Helena Foulkes||EVP||Sell||53,546||$60.00||$3,212,760.00||7,897|| |
|9/9/2013||Helena Foulkes||EVP||Sell||47,568||$58.65||$2,789,863.20|| |
|9/4/2013||Andrew Sussman||SVP||Sell||9,020||$58.36||$526,407.20||3,128|| |
|10/4/2012||Andrew Sussman||SVP||Sell||9,020||$49.00||$441,980.00|| |
|10/1/2012||Thomas M Moriarty||EVP||Buy||6,164||$48.67||$300,001.88|| |
|9/13/2012||David M Denton||CFO||Sell||11,526||$47.00||$541,722.00|| |
|8/21/2012||Jean Pierre Millon||Director||Sell||33,726||$45.73||$1,542,289.98|| |
CVS Health (NYSE CVS) News Headlines
CVS Health (NYSE:CVS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CVS Health (NYSE:CVS) Income Statement, Balance Sheet and Cash Flow Statement
CVS Health (NYSE CVS) Stock Chart for Monday, January, 22, 2018